Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brii BiosciencesFRA:7SS +1.04%33 3-Year EBITDA Growth Rate is 23.30% as of Dec. 2025, which is 37% below its 10-year median of 37.05. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Brii Biosciences ranks better than 60.12% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 41.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Brii Biosciences was 60.20% per year. The lowest was 3.40% per year. And the median was 37.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Brii Biosciences 3-Year EBITDA Growth Rate Related Terms
FRA:7SS vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Brii Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.30% mean?
Brii Biosciences (FRA:7SS) has a 3-Year EBITDA Growth Rate of 23.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Brii Biosciences and its competitors. This is 37% below median its historical median of 37.05. Over the past decade, Brii Biosciences' 3-Year EBITDA Growth Rate has ranged from 3.40 to 60.20. According to the industry distribution chart, Brii Biosciences ranks #451 out of 1131 companies in the Biotechnology industry, placing it in the top 39.9%.
Is Brii Biosciences' 3-Year EBITDA Growth Rate too high?
Brii Biosciences' current 3-Year EBITDA Growth Rate of 23.30% is 37% below median its 10-year median of 37.05. Over the past 10 years, this metric has ranged from a low of 3.40 to a high of 60.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Brii Biosciences' value of 23.30% is 56.4% above this industry median. Based on the distribution chart, Brii Biosciences ranks #451 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #451 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts Brii Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Brii Biosciences' value of 23.30% is 56.4% above this benchmark. Historically, Brii Biosciences' own 3-Year EBITDA Growth Rate has ranged from 3.40 to 60.20 over the past decade. While the company's 10-year median is 37.05 vs. the industry median of 14.90, Brii Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current 3-Year EBITDA Growth Rate of 23.30% is 56.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Brii Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current 3-Year EBITDA Growth Rate is 23.30%, which is 37% below median its own 10-year median of 37.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current 3-Year EBITDA Growth Rate of 23.30%. The current 3-Year EBITDA Growth Rate is 23.30%, which is 37% below median its 10-year median of 37.05 and 56.4% above the Biotechnology industry median of 14.90. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current 3-Year EBITDA Growth Rate is 23.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
